Understanding the science behind Immuno-Oncology

Using the body’s natural immune response to fight cancer

For more information, please visit IOHCP.com
Revealing the potential of the immune system in cancer

Introduction to the tumor microenvironment and the immune response

The immune system is able to recognize foreign threats (nonself) as distinct from normal cells (self). Innate and adaptive immunity act as complementary networks of self-defense against foreign threats, such as pathogens and cancer.

In cancer, normal cells have mutated into tumor cells and are recognized as nonself by both the innate and adaptive immune systems.

Antitumor activity of the innate and adaptive immune responses

Innate immune response

The first line of defense. It rapidly identifies and attacks tumor cells without antigen specificity. It recognizes activating and inhibitory signals from target cells to distinguish self from nonself. NK cells are the main effector cells of the innate immune system.

Adaptive immune response

An antigen-specific and durable response. Once activated, it can be sustained through immune memory. Cytotoxic T cells are effector cells of the adaptive immune system.
Key stages of the antitumor immune response

In both the innate and adaptive immune responses, immune cells have the potential to recognize and eliminate tumor cells. There are three principal stages in this process:

**Presentation**
- The innate immune system rapidly identifies and attacks tumor cells. Tumor cell death releases tumor antigens, which can activate the cytotoxic T cells of the adaptive immune system.14,15

**Infiltration**
- Tumor antigens and other factors attract immune cells to the tumor site, where they invade and attack.14

**Elimination**
- Activated cytotoxic T cells recognize tumor cells as the source of the antigen and target them for elimination.14

Tumor cells can evade and suppress immune activity

The complex network of activating and inhibitory pathways enables the antitumor immune response to detect and eliminate tumor cells at any point in tumor development.14 However, tumors seek to evade or suppress the body’s natural ability to fight cancer, and they can evolve at any phase of growth to “outsmart” the antitumor immune response.15,17

The tumor microenvironment consists of different cell types that help tumor cells evade antitumor immune activity.16,19 As tumors evolve, they can influence the activation and composition of cells within the tumor microenvironment.17

Immune pathways combine to refine response

The three stages of the immune response—presentation, infiltration, and elimination—are regulated through a network of activating and inhibitory signaling pathways that combine to maintain immune balance.3,15,20 Establishing fundamental stages of immune response that are impaired within noninflamed tumors is a strategy to improve the broad potential of I-O.

Various components of the immune system and the tumor microenvironment, including APCs, immune regulatory cells, stromal cells, and the tumor itself, regulate the ability of effector cells to eliminate tumors.3,20-22 Ongoing I-O research at Bristol Myers Squibb is exploring how targeting these components, either alone or in combination, may restore the body’s natural ability to fight cancer.

Deep insight into tumor-intrinsic signaling and immune biology continues to inform and inspire discoveries—enabling the development of novel combination therapies.
Modulating a combination of signaling pathways can more efficiently promote antitumor activity than either pathway alone, as suggested by preclinical data.23-27

Select pathways that modulate tumor detection

Tumors use several mechanisms to avoid detection by the immune system.28,29 Current research is investigating modulation of pathways, including those involved in antigen presentation and phagocytosis, to promote better tumor cell recognition.28,29

STING is an intracellular protein expressed in APCs such as DCs, which serves as an innate immune activator that stimulates APCs to drive cytotoxic T-cell activity.30,31

FucGM1 is a ganglioside that is highly expressed on the surface of certain cancer cells and enables cell communication.35-37

NLRP3 is a protein expressed in APCs, such as DCs, monocytes, and macrophages.32 NLRP3 is involved in the assembly of the NLRP3 inflammasome, a protein complex that is a key mediator of innate immunity and the priming of T cells.33,34

Select pathways that modulate immunosuppression

Some tumors can avoid destruction by thriving in an immunosuppressive environment and dampening the immune response.38,39 Current research is investigating modulation of pathways that regulate immunosuppressive activity in order to increase antitumor response.38,39

CTLA-4 is an immune checkpoint receptor on activated T cells and Tregs that inhibits T-cell activation.40-42 Binding of CTLA-4 on cytotoxic T cells to CD80/86 on APCs inhibits T-cell activation.43,44

CCR2 and CCR5 regulate the recruitment of immunosuppressive cells through the stroma.45-46 CCR2 and CCR5 are both expressed on the surface of T cells, Tregs, monocytes, MDSCs, and TAMs.47-52

IL-8 is a cytokine produced by macrophages, monocytes, and stromal cells that promotes the recruitment of immunosuppressive MDSCs and, during the normal healing process, activates the angiogenic response to generate new blood vessels.53-56

REVEALING THE POTENTIAL OF THE IMMUNE SYSTEM IN CANCER
Select pathways that modulate effector cell function

Various components of the immune system and tumor microenvironment regulate effector cell ability to eliminate tumors. Current research is investigating the following pathways involved in the regulation of effector cells in order to enhance their activity.28,57

**PD-1** is an immune checkpoint receptor on cytotoxic T cells that plays a key role in T-cell exhaustion and prevention of autoimmunity.58-62

**CTLA-4** is an immune checkpoint receptor that, in addition to being expressed on activated T cells, is also found on Tregs, where it is a key driver of their ability to suppress the immune response. Tumor cells utilize the CTLA-4 pathway to suppress the immune response, decreasing T-cell activation and ability to proliferate into memory T cells.21,40,41,63-65

**TIM-3** is an immune checkpoint receptor involved in the suppression of both innate and adaptive immune cells.75-77 It is expressed on the surface of a wide variety of immune cells, including cytotoxic T cells, Tregs, NK cells, and some APCs, such as DCs.75,76

**LAG-3** is an immune checkpoint receptor on the surface of both activated cytotoxic and regulatory T cells.66-68 LAG-3 can negatively regulate T-cell proliferation and promote T-cell exhaustion.69-71

**TIGIT** is an immune checkpoint receptor expressed on the surface of cytotoxic and memory T cells, Tregs, and NK cells.22,23 On all of these cells, TIGIT can play a role in immune suppression.22,76

**SLAMF7** is an activating receptor on the surface of NK cells and other immune cells.78 When engaged, SLAMF7 activates NK cells, the rapid responders of the immune system and the body’s first line of defense against cancer.79

**IL-2** is an activating receptor expressed on the surface of immune cells including cytotoxic T cells, NK cells, and Tregs.80-83 The interaction of IL-2 with its receptor, IL-2R, promotes the activation and proliferation of various immune cells.82,83

**CTLA-4** is an immune checkpoint receptor that, in addition to being expressed on activated T cells, is also found on Tregs, where it is a key driver of their ability to suppress the immune response. Tumor cells utilize the CTLA-4 pathway to suppress the immune response, decreasing T-cell activation and ability to proliferate into memory T cells.21,40,41,63-65

**IDO1** is an enzyme expressed in tumor cells and APCs.90,91 It metabolizes tryptophan, an amino acid that is essential for T-cell survival, into immunosuppressive kynurenine, which normally acts as a counterbalance to suppress T cells and prevent overactivation of the immune response.90,92-94

Select tumor cell pathways

Various signaling and metabolic pathways intrinsic to tumor cells can drive oncogenesis and tumor growth. Current research is investigating blocking these pathways in order to promote tumor cell death.95-96

**BET** is a family of proteins that are widely expressed and are responsible for regulating a variety of cellular processes.97-100 In cancer, they upregulate the transcription of c-Myc, which is a major factor in the regulation of tumor proliferation.101

**LSD1** is a demethylating enzyme that potentially plays a role in nucleosome remodeling, which may regulate genes critical to stem cell differentiation and cancer development.102-104
Discovering the possibilities of Immuno-Oncology biomarkers

Biomarkers in I-O research

With a focus on precision medicine, our research and development program aims to rapidly translate research into novel regimens to accelerate delivery of the right treatment, for the right patient, at the right time. Biomarkers are biologic molecules, cells, or processes found in tissues or body fluids (such as blood) that are a sign of a normal or abnormal process or disease.\textsuperscript{105,106}

I-O biomarkers are a class of biomarker that can help evaluate an active antitumor immune response within the body.\textsuperscript{107} I-O biomarkers can be prognostic, predictive, or pharmacodynamic, or a combination\textsuperscript{108-111}:

Prognostic biomarkers may identify the likelihood of a clinical event, such as disease progression, disease recurrence, or death, independent of the therapy received.\textsuperscript{108,109}

Predictive biomarkers may identify whether individuals are more likely to experience a favorable or unfavorable response to treatment.\textsuperscript{108,109}

Pharmacodynamic biomarkers may show that a biologic response has occurred in an individual who has received treatment.\textsuperscript{109,110}

As we continue to learn more about cancer biology—and with advancements in high-throughput technologies—the goal of I-O biomarker testing will be to provide actionable information toward developing personalized I-O therapy, including combinations with other treatment modalities.\textsuperscript{112,113}

Bristol Myers Squibb aims to identify clinical characteristics and I-O biomarkers to determine the patient populations most likely to benefit from I-O therapy.\textsuperscript{112,114} I-O biomarker research aims to further characterize the unique interplay between the immune system and tumor cells in the following categories:

**Tumor antigens**
Tumor antigens are recognized as nonself or foreign by the host immune system and can initiate the adaptive immune response

- TMB | MSI-H/dMMR
- Inflamed tumors
  - Inflamed tumors show evidence of immune-cell infiltration and activation in the tumor microenvironment
  - PD-L1 | PD-L2 | TILs | Inflammation gene signatures

**Immune suppression**
Cells and proteins within the tumor and its microenvironment are associated with inhibition of the antitumor immune response

- LAG-3 | Tregs | MDSCs

As I-O biomarkers are dynamic and complex, the presence or absence of any single I-O biomarker may not provide a complete understanding of the diverse interactions occurring within the tumor microenvironment.\textsuperscript{114-116}

A composite I-O biomarker evaluation may provide a more comprehensive assessment of immune status.\textsuperscript{114}
Evolving clinical expectations in Immuno-Oncology

I-O is a different approach that fights cancer by targeting the immune system

Treatment approaches currently approved to fight cancer include chemotherapy, radiation, targeted therapy, and immunotherapy. Radiation, chemotherapy, and targeted therapy are all directed toward killing tumor cells.\textsuperscript{117-120}

In contrast, I-O seeks to activate the body’s natural immune response to fight cancer. This is a fundamentally different approach to cancer treatment.\textsuperscript{121}

With this approach comes unique considerations and distinctive characteristics that continue to be researched, such as:

- Immune responses having the potential to deepen and sustain over time
- Resistance to immunotherapy, which can be present at the start of treatment or form over time
- Unique patterns of response, such as pseudoprogression
- Comprehensive endpoint considerations
- Immune-mediated adverse reactions
Resistance to immunotherapy can be present at the start of treatment or form over time

Advances in immunotherapy have resulted in enhanced antitumor responses. A significant challenge is the development of resistant disease and disease progression during or after therapy.17,122

As tumors evolve over time, they can influence the activation and composition of cells within the tumor microenvironment.17,122 Some tumors do not respond from the beginning of treatment with immunotherapies, and this is termed “primary resistance.” In contrast, “acquired resistance” describes tumors that initially respond to immunotherapies, but then fail to respond after a period of time.123

Identification of mechanisms of immunotherapy resistance is an area of research that will inform appropriate treatment options for patients.

Pseudoprogression may reflect development of antitumor immunity

The nature of the antitumor immune response can create the appearance of disease progression, either as tumor growth or appearance of new lesions.124,125 This is known as pseudoprogression: this does not reflect tumor cell growth, but may be misclassified as disease progression.124,126,127

Bristol Myers Squibb is committed to understanding the tumor immune response and exploring mechanisms underlying primary and secondary acquired resistance.

**Baseline assessment**  **First assessment**  **Later assessment**

<table>
<thead>
<tr>
<th>Disease progression</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.png" alt="image" /></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pseudoprogression (nonconventional response)</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image2.png" alt="image" /></td>
</tr>
</tbody>
</table>

Tumors may appear to grow or new lesions may appear when immune cells infiltrate the tumor site.126 Due to the time required to mount an adaptive immune response, pseudoprogression may also reflect continued tumor growth until a sufficient response develops.124,128
Pseudoprogression should be considered until disease progression can be confirmed

While uncommon, pseudoprogression is an important consideration when evaluating response to I-O therapies. Histologic confirmation is not always possible, but close monitoring of the following factors may help identify pseudoprogression:

<table>
<thead>
<tr>
<th>Disease progression</th>
<th>Pseudoprogression (nonconventional response)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Performance status</strong></td>
<td>Deterioration of performance</td>
</tr>
<tr>
<td><strong>Systemic symptoms</strong></td>
<td>Worsen</td>
</tr>
<tr>
<td><strong>Symptoms of tumor enlargement</strong></td>
<td>Present</td>
</tr>
<tr>
<td><strong>Tumor burden</strong></td>
<td>Increase</td>
</tr>
<tr>
<td><strong>Baseline</strong></td>
<td>Appear and increase in size</td>
</tr>
<tr>
<td><strong>New lesions</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Biopsy may reveal</strong></td>
<td>Evidence of tumor growth</td>
</tr>
</tbody>
</table>

Endpoint considerations for I-O research

The criteria currently used to assess potential benefit of cancer therapies are based on surgery, radiation therapy, and chemotherapy. However, for I-O—a different way to fight cancer—a more comprehensive approach to endpoint assessment may be needed to recognize potential benefit.

- Overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) are among endpoints used to measure outcomes in oncology research. OS is the gold standard to assess therapeutic benefit when possible.
- In addition, key measures of response are magnitude (size)—measured as the proportion of patients with a predefined decrease in tumor burden, called the ORR—and duration (time)—assessed as the time from initial tumor response to disease progression, called the duration of response (DOR).
- Finally, other measures such as treatment-free survival (TFS) and patient-reported outcomes (PROs) may also integrate a patient’s QOL. TFS measures the time a patient spends off treatment, while incorporating QOL and toxicities experienced. PROs evaluate the impact of treatment on QOL based on the patient’s own account.

Assessing multiple measures can illustrate the full scope of clinical benefit.
Immune responses have the potential to deepen and sustain over time

The immune response evolves and expands over time by constantly recognizing and remembering tumor antigens. This ability—to propagate and perpetuate—suggests the adaptive nature of the immune response. Immune responses are dynamic and have the potential to improve and deepen over time.

Immune-mediated adverse reactions

I-O therapies that modulate immune pathways may enable the immune system to attack healthy cells along with tumor cells. The effects are known as immune-mediated adverse reactions. When managing complications of immune-mediated adverse reactions, please consider:

- Patients, caregivers, and physicians should be educated to remain vigilant throughout and after I-O treatment to potentially minimize complications, some of which may be life-threatening.
- Treatment algorithms are available for use by healthcare providers to assist them in managing immune-mediated adverse reactions.
- Recent guidelines have been published that provide consensus recommendations for the management of immune-mediated adverse reactions. Specific guidance for managing immune-mediated adverse reactions for an individual product can be found in the accompanying FDA-approved Prescribing Information.

As research in immunotherapy advances and more data are made available, understanding and effective management of immune-mediated adverse reactions will evolve.
Realizing the potential of Immuno-Oncology research

Depth of evidence for the immune response to cancer

Both solid tumors and hematologic malignancies are able to induce an immune response that can regulate their initial growth. This ability is known as tumor immunogenicity. The body is able to recognize and attack cancer through the following stages of immune response:

**Presentation**
There is a broad range of tumors that are traditionally defined by high rates of mutations. These mutations create neoantigens that can be recognized by the immune system, activating an antitumor immune response.

**Infiltration**
Tumor-infiltrating immune cells are present in the tumor microenvironment. Their presence demonstrates their capacity to identify and migrate to tumor cells.

**Elimination**
Early in their development, some tumors display evidence of spontaneous regression. This suggests that the immune system is able to recognize and eliminate some tumor cells and supports the concept that the body’s own immune system has the ability to induce an antitumor response against cancer.

---

### Broad potential of I-O research

Evidence for tumor immunogenicity across a wide range of solid tumors and hematologic malignancies provides the rationale for the breadth of I-O research across tumor types:

<table>
<thead>
<tr>
<th>Tumor type*</th>
<th>Presentation</th>
<th>Infiltration</th>
<th>Elimination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bladder</td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Breast</td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Colorectal</td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Gastric/esophageal</td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Glioblastoma</td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Head and neck</td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Hepatocellular</td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Lung</td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Melanoma</td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Ovarian</td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Pancreatic</td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Prostate</td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Renal</td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Leukemia</td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
</tbody>
</table>

*List of tumors represents common types of cancer but is not exhaustive.
I-O research is constantly evolving

Some of the ongoing research at Bristol Myers Squibb focuses on:

- Building an understanding of the dynamic mechanisms that govern the immune system’s response to cancer
- Understanding the role of immune signaling pathways, either alone or in combination, and how they can be modulated to restore the body’s natural ability to fight cancer
- Identifying I-O biomarkers that clarify the unique interplay between the immune system and the tumor that may help to optimize personalized medicine and improve patient outcomes
- Developing a more comprehensive approach to endpoint assessment, to better recognize the potential benefit of I-O research

The potential of I-O research continues to expand, driven by the many patients with advanced cancer who await the offer of renewed hope and the potential of a longer life.

For more detailed information on the science behind I-O, please visit IOHCPC.com.

References


REFERENCES
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>APC</td>
<td>antigen-presenting cell</td>
</tr>
<tr>
<td>BET</td>
<td>bromodomain and extraterminal domain</td>
</tr>
<tr>
<td>CCR2</td>
<td>chemokine (C-C motif) receptor 2</td>
</tr>
<tr>
<td>CCR5</td>
<td>chemokine (C-C motif) receptor 5</td>
</tr>
<tr>
<td>CTLA-4</td>
<td>cytotoxic T-lymphocyte antigen 4</td>
</tr>
<tr>
<td>DC</td>
<td>dendritic cell</td>
</tr>
<tr>
<td>dMMR</td>
<td>mismatch repair deficient</td>
</tr>
<tr>
<td>FucGM1</td>
<td>fucosyl GM1</td>
</tr>
<tr>
<td>IDO1</td>
<td>indoleamine 2,3-dioxygenase-1</td>
</tr>
<tr>
<td>Ig</td>
<td>immunoglobulin</td>
</tr>
<tr>
<td>IL-2</td>
<td>interleukin-2</td>
</tr>
<tr>
<td>IL-8</td>
<td>interleukin-8</td>
</tr>
<tr>
<td>I-O</td>
<td>Immuno-Oncology</td>
</tr>
<tr>
<td>ITIM</td>
<td>immunoreceptor tyrosine-based inhibitory motif</td>
</tr>
<tr>
<td>LAG-3</td>
<td>lymphocyte-activation gene 3</td>
</tr>
<tr>
<td>LSD1</td>
<td>lysine specific demethylase 1</td>
</tr>
<tr>
<td>MHC</td>
<td>major histocompatibility complex</td>
</tr>
<tr>
<td>MSI-H</td>
<td>microsatellite instability-high</td>
</tr>
<tr>
<td>NK</td>
<td>natural killer</td>
</tr>
<tr>
<td>NLRP3</td>
<td>nucleotide-binding oligomerization domain-like receptor family, pyrin domain containing 3</td>
</tr>
<tr>
<td>PD-1</td>
<td>programmed death receptor-1</td>
</tr>
<tr>
<td>PD-L1</td>
<td>programmed death ligand 1</td>
</tr>
<tr>
<td>PD-L2</td>
<td>programmed death ligand 2</td>
</tr>
<tr>
<td>QOL</td>
<td>quality of life</td>
</tr>
<tr>
<td>SLAMF7</td>
<td>signaling lymphocytic activation molecule family member 7</td>
</tr>
<tr>
<td>STING</td>
<td>stimulator of interferon genes</td>
</tr>
<tr>
<td>TAM</td>
<td>tumor-associated macrophage</td>
</tr>
<tr>
<td>TIGIT</td>
<td>T-cell immunoreceptor with Ig and ITIM domains</td>
</tr>
<tr>
<td>TIL</td>
<td>tumor-infiltrating lymphocyte</td>
</tr>
<tr>
<td>TIM-3</td>
<td>T-cell immunoglobulin mucin-3</td>
</tr>
<tr>
<td>TMB</td>
<td>tumor mutational burden</td>
</tr>
<tr>
<td>Treg</td>
<td>regulatory T cell</td>
</tr>
</tbody>
</table>